Drugs / AVP-923
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02402595 | Mar → Jul 2015 | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT02336347 Comparator | May → Sep 2014 | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02174835 Comparator | Sep → Nov 2013 | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01787747 Background | Oct 2012 → Feb 2013 | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVP-923 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02402595 ↗ |
| Route | Oral | “Twice daily dosing orally for 7 days” NCT02174835 ↗ |